Portal for patients

​Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion

Bristol-Myers Squibb agreed to buy all circulating shares of biotechnology company Flexus, specializing in the creation of innovative treatments for cancer. The transaction value is estimated at $ 1.25 billion.

Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion

In an official press release it is noted that at the same time Bristol-Myers Squibb will pay $800 million, while another $450 million will be paid after the execution of certain tasks in the development of new anti-cancer drugs. The transaction has been approved by the boards of directors of both companies and the holders of securities Flexus.

The acquisition will allow Flexus Bristol-Myers Squibb to expand its portfolio of drugs for cancer immunotherapy, including the right to receive a promising experimental tool F001287 (inhibitor IDO1).

Also, Bristol-Myers Squibb announced the signing of a cooperation agreement with Rigel Pharmaceuticals. According to the agreement, the companies will work together to engage in research, development and commercialization of drugs for cancer immunotherapy.

See also:

No comments

Application for treatment
MTEC 2019 (eng.-com)